Physician profile
Sarah E Abraham
NPI 1518293448
$14,123.34
in general payments reported to CMS, 2019-2025
30 companies · $3,536 in 2025
The $3,536 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,177 · 2022: $1,263 · 2023: $2,597 · 2024: $4,550 · 2025: $3,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,554 · Consulting Fee: $850 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,553.64 |
| Consulting Fee | $850.00 |
| Education | $279.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,698.15 | 2022-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,812.02 | 2021-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,460.83 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $810.14 | 2021-2025 | Dupixent |
| Incyte Corporation | $747.93 | 2021-2025 | Opzelura |
| Amgen INC. | $710.12 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $691.91 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $666.44 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Novartis Pharmaceuticals Corporation | $584.92 | 2021-2025 | |
| Leo Pharma INC. | $571.00 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $547.80 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $389.11 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $387.54 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $246.34 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $245.21 | 2023-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $230.74 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $200.18 | 2021-2025 | Jublia, Cabtreo |
| Pfizer INC. | $189.06 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $149.98 | 2021-2022 | |
| Epi Health, LLC | $145.01 | 2021 | |
| Vyne Pharmaceuticals INC. | $139.40 | 2021 | |
| Organon LLC | $128.05 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $127.32 | 2021-2024 | Winlevi |
| Mayne Pharma Commercial LLC | $105.00 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $35.24 | 2023-2025 | Ycanth |
| Botanix Sb INC | $32.54 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.47 | 2025 | Spevigo |
| Fresenius Kabi USA, LLC | $19.89 | 2024 | Idacio |
| Allergan, INC. | $18.79 | 2022 | |
| Nabriva Therapeutics, Plc | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.